| Literature DB >> 33443214 |
Hany S Girgis1, Cory D DuPai2, Jessica Lund3, Janina Reeder2, Joseph Guillory3, Steffen Durinck4, Yuxin Liang3, Joshua Kaminker2, Peter A Smith5, Elizabeth Skippington6.
Abstract
Tandem gene amplification is a frequent and dynamic source of antibiotic resistance in bacteria. Ongoing expansions and contractions of repeat arrays during population growth are expected to manifest as cell-to-cell differences in copy number (CN). As a result, a clonal bacterial culture could comprise subpopulations of cells with different levels of antibiotic sensitivity that result from variable gene dosage. Despite the high potential for misclassification of heterogenous cell populations as either antibiotic-susceptible or fully resistant in clinical settings, and the concomitant risk of inappropriate treatment, CN distribution among cells has defied analysis. Here, we use the MinION single-molecule nanopore sequencer to uncover CN heterogeneity in clonal populations of Escherichia coli and Acinetobacter baumannii grown from single cells isolated while selecting for resistance to an optimized arylomycin, a member of a recently discovered class of Gram-negative antibiotic. We found that gene amplification of the arylomycin target, bacterial type I signal peptidase LepB, is a mechanism of unstable arylomycin resistance and demonstrate in E. coli that amplification instability is independent of RecA. This instability drives the emergence of a nonuniform distribution of lepB CN among cells with a range of 1 to at least 50 copies of lepB identified in a single clonal population. In sum, this remarkable heterogeneity, and the evolutionary plasticity it fuels, illustrates how gene amplification can enable bacterial populations to respond rapidly to novel antibiotics. This study establishes a rationale for further nanopore-sequencing studies of heterogeneous cell populations to uncover CN variability at single-molecule resolution.Entities:
Keywords: amplification; antibiotic resistance; heterogeneity; optimized arylomycins
Mesh:
Substances:
Year: 2021 PMID: 33443214 PMCID: PMC7817135 DOI: 10.1073/pnas.2021958118
Source DB: PubMed Journal: Proc Natl Acad Sci U S A ISSN: 0027-8424 Impact factor: 11.205
Fig. 1.Variable CN of an ∼4.8-kb tandem repeat containing bacterial signal peptidase gene lepB. (A) E. coli ATCC strain 25922 gene map, with depth of mapped Illumina reads shown. The blue rectangle indicates the tandem repeat unit. (B) Sixty MinION reads that traverse the entire tandem array, with black horizontal lines representing reads and line length proportional to read length. Individual copies of the ∼4.8-kb repeat unit are show as blue rectangles. (C) Number of lepB copies per MinION read, for reads that traverse or partially overlap with the tandem array.
Fig. 2.Variable CN of amplified regions containing lepB in three arylomycin-resistant A. baumannii mutants. (A) A. baumannii ATCC strain 17978 gene map, with depth of mapped Illumina reads shown. The solid blue rectangles indicate the sizes of the amplified chromosomal regions detected. The lepB gene is shown in red. (B) Schematic representation of the 13-kb amplified region in mutant 1 with interleaving IS element, ISAba12, shown in yellow. Genes interrupted by the ISAba12 insertion are shown with dotted outlines. (C) Number of lepB copies per MinION read, for reads that traverse or partially overlap with repeat arrays.
Fig. 3.Serial passaging of E. coli mutants containing lepB amplifications. (A) Experimental design of serial-passaging experiment in which recA::kan and recA WT amplification mutants were passaged for 7 d with or without LepB inhibitor G0775. Passages performed in the presence of G0775 used a concentration of either 0.5 or 1.0 μg/mL. (B) Boxplots of the average number of lepB copies per cell in mutant populations, as determined by Illumina sequencing before and after 7-d passage—the boxes extend from the 25th to the 75th percentile and encompass the median (horizontal line). **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.001 (Wilcoxon rank-sum test with Holm correction for multiple comparisons); no asterisk means not significant. (C) Boxplots of the average number of lepB copies per cell in mutant populations by the MIC of G0775. No asterisk means not significant (Wilcoxon rank-sum test). (D) Number of lepB copies per MinION read, for reads that traverse or partially overlap with the lepB tandem repeat array after 7 d of passage without G0775.
Genomic variation and resistance of E. coli mutant populations serial passaged for 7 d either with or without LepB inhibitor, G0775
| Strain | Day 0 | Day 7 | ||||||||||
| Passaged in 0 μg/mL | Passaged in 0.5 μg/mL | Passaged in 1 μg/mL | ||||||||||
| MIC | SVNs | MIC | SVNs | MIC | SVNs | MIC | SVNs | |||||
| WT | 0.25 | 1 | None | — | — | — | — | — | — | — | — | — |
| Δ | 0.25 | 1 | None | — | — | — | — | — | — | — | — | — |
| Replicate 1 | 2 | 10 | — | 2 | 4 | 8 | 14 | — | 16 | 27 | — | |
| Replicate 2 | 2 | 11 | — | 2 | 4 | 8 | 15 | — | 16 | 35 | ||
| Replicate 3 | 2 | 10 | — | 2 | 4 | 8 | 14 | 16 | 27 | — | ||
| A | 2 | 34 | 2 | 6 | — | 4 | 35 | 4 | 39 | |||
| B | 2 | 36 | — | 1 | 2 | — | 4 | 41 | 4 | 40 | ||
| C | 2 | 32 | — | 2 | 2 | 4 | 45 | 4 | 43 | — | ||
| D | 2 | 32 | 1 | 3 | g.3112313C > T - upstream of DR76_RS15030 (94%) | 4 | 53 | 4 | 44 | |||
| E | 2 | 31 | 1 | 2 | 2 | 40 | 8 | 39 | ||||
| F | 2 | 25 | 1 | 4 | 2 | 38 | 2 | 37 | ||||
| G | 2 | 17 | 1 | 4 | 2 | 41 | 4 | 44 | ||||
| H | 2 | 17 | 1 | 6 | 2 | 44 | 4 | 44 | ||||
| I | 2 | 27 | g.4953334_4953335insG - upstream of DR76_RS24600 (80%) | 1 | 7 | 4 | 42 | 8 | 20 | g.4953334_4953335insG - upstream of DR76_RS24600 (77%) | ||
| g.4953334_4953335insG - upstream of DR76_RS24600 (80%) | ||||||||||||
| J | 2 | 12 | — | 2 | 9 | — | 4 | 52 | 4 | 49 | — | |
| K | 2 | 5 | 1 | 5 | 4 | 28 | 8 | 28 | ||||
Mutants were selected as described in Fig. 3. Only variants present in at least 50% of mapped reads at the site of variation are reported, and the frequency of each variant is indicated in parentheses.
MIC.
Average CN estimated using Illumina sequencing data.
Single nucleotide variants.
Insertions/deletions.